Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635984 · ClinicalTrials.gov registry record · Phase 3
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
A Phase 3 study of Hematologic Neoplasms and Complications of Bone Marrow Transplant, sponsored by Augusta University.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT02635984 is a Phase 3 study of Hematologic Neoplasms and Complications of Bone Marrow Transplant that has completed, run by Augusta University. The registered enrollment target is 108 participants, below the 1,021-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02635984, a Phase 3 study of Hematologic Neoplasms and Complications of Bone Marrow Transplant, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea and vomiting (CINV) in hematology patients receiving highly or moderately emetogenic chemotherapy regimens.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olanzapine
Study Locations (1)
Georgia
- Augusta University Medical Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635984
The ClinicalTrials.gov registry entry for NCT02635984 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,021-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (89% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02635984 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02635984 about?
NCT02635984 is a clinical study titled "Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens". The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea and vomiting (CINV) in hematology patients receiving highly or moderately...
What is the current status of trial NCT02635984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2015-11. Estimated completion is 2017-12.
What conditions does trial NCT02635984 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, Complications of Bone Marrow Transplant.
What interventions are being tested in trial NCT02635984?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT02635984?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02635984 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
UWCCC Molecular Tumor Board Registry
RECRUITING
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.